• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Why OpGen Shares Are Trading Higher By 220%? Here Are 64 Stocks Moving In Tuesday's Mid-Day Session

    12/13/22 12:14:33 PM ET
    $ACMR
    $AMAM
    $ANGI
    $APVO
    Industrial Machinery/Components
    Technology
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $ACMR alert in real time by email

    Gainers

    • OpGen, Inc. (NASDAQ:OPGN) shares surged 220% to $0.3994 after the company announced topline data from its Unyvero urinary tract infections (UTI) clinical trial.
    • Netcapital Inc. (NASDAQ:NCPL) shares jumped 100% to $2.77 following Q2 results. Netcapital posted Q2 earnings of $0.04 per share on sales of $1.78 million.
    • Onion Global Limited (NYSE:OG) gained 65% to $0.33.
    • Jiuzi Holdings, Inc. (NASDAQ:JZXN) shares jumped 46.7% to $0.2171.
    • Faraday Future Intelligent Electric Inc. (NASDAQ:FFIE) rose 33.3% to $0.6119 after surging over 55% on Monday. Faraday Future Intelligent Electric recently appointed FF China CEO Xuefeng (XF) Chen as Global CEO of the company
    • BeyondSpring Inc. (NASDAQ:BYSI) jumped 31% to $0.9995 after the company presented data with plinabulin for the prevention of docetaxel-induced neutropenia in patients with non-small cell lung cancer and breast cancer at three medical conferences.
    • Fluence Energy, Inc. (NASDAQ:FLNC) shares gained 28% to $22.05 after the company reported better-than-expected Q4 sales.
    • Shineco, Inc. (NASDAQ:SISI) jumped 27% to $1.6518 after the company announced its subsidary was granted a USPTO patent and FDA marketing approval for its in-situ fecal specimen sampling device.
    • Gritstone bio, Inc. (NASDAQ:GRTS) gained 27% to $3.2807. Gritstone bio was granted two new US patents for self-amplifying mRNA.
    • Prenetics Global Limited (NASDAQ:PRE) rose 27% to $2.35. Prenetics recently announced a $20 million buyback.
    • SenesTech, Inc. (NASDAQ:SNES) gained 26% to $3.13.
    • Magenta Therapeutics, Inc. (NASDAQ:MGTA) gained 25.2% to $1.44 after the company highlighted updated data from the ongoing MGTA-117 Phase 1/2 dose-escalation trial at the American Society of Hematology 2022 Annual (ASH) Meeting.
    • Grom Social Enterprises, Inc. (NASDAQ:GROM) rose 24.8% to $1.65.
    • ClearSign Technologies Corporation (NASDAQ:CLIR) jumped 24.8% to $0.69.
    • Moderna, Inc. (NASDAQ:MRNA) surged 22.8% to $202.86 after the company and Merck announced mRNA-4157/V940 in combination with KEYTRUDA, met the primary efficacy endpoint in the Phase 2b KEYNOTE-942 trial.
    • Schrödinger, Inc. (NASDAQ:SDGR) rose 22.6% to $20.88.
    • Dada Nexus Limited (NASDAQ:DADA) gained 21.7% to $8.02. Shares of Chinese companies traded higher following the recent easing of Covid restrictions in China, which has helped increase travel activity.
    • MamaMancini's Holdings, Inc. (NASDAQ:MMMB) rose 21.4% to $1.5308 following better-than-expected Q3 results.
    • Ventyx Biosciences, Inc. (NASDAQ:VTYX) rose 21.4% to $34.70 after gaining over 5% on Monday.
    • Rallybio Corporation (NASDAQ:RLYB) shares climbed 19.8% to $10.43. JP Morgan, last week, initiated coverage on Rallybio with an Overweight rating and announced a price target of $21.
    • ACM Research, Inc. (NASDAQ:ACMR) gained 19.6% to $10.43.
    • Wave Life Sciences Ltd. (NASDAQ:WVE) gained 19.4% to $4.3115. Wave Life Sciences and GSK plc have announced a strategic collaboration to advance oligonucleotide therapeutics, including Wave's preclinical RNA editing program targeting alpha-1 antitrypsin deficiency, WVE-006.
    • Kaspien Holdings Inc. (NASDAQ:KSPN) rose 19.1% to $0.8799.
    • Entrada Therapeutics, Inc. (NASDAQ:TRDA) jumped 18% to $19.16. Vertex Pharmaceuticals and Entrada Therapeutics recently announced a global collaboration focused on discovering and developing intracellular Endosomal Escape Vehicle (EEV) therapeutics for myotonic dystrophy type 1 (DM1).
    • Summit Therapeutics Inc. (NASDAQ:SMMT) gained 16.6% to $3.29.
    • 180 Life Sciences Corp. (NASDAQ:ATNF) rose 15.5% to $0.3101.
    • National Western Life Group, Inc. (NASDAQ:NWLI) gained 14.8% to $277.01.
    • 2U, Inc. (NASDAQ:TWOU) gained 14.1% to $7.95.
    • Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) jumped 13.1% to $11.38.
    • Ribbon Communications Inc. (NASDAQ:RBBN) surged 12.5% to $2.98.
    • Gaotu Techedu Inc. (NASDAQ:GOTU) gained 12% to $1.87. Gaotu Techedu, last month, reported a third-quarter FY22 sales decline of 45.6% year-on-year to RMB606.2 million ($85.21 million).
    • Mullen Automotive, Inc. (NASDAQ:MULN) jumped 11.5% to $0.2152 after the company announced it signed its first U.S. dealer partner.
    • Pinterest, Inc. (NYSE:PINS) climbed 10.6% to $26.12. Piper Sandler upgraded Pinterest from Neutral to Overweight and raised the price target from $25 to $30.
    • ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) gained 10.1% to $7.84 after SVB Leerink initiated coverage on the stock with an Outperform rating and a $14 price target.
    • Angi Inc. (NASDAQ:ANGI) gained 9.7% to $2.3250 after Citigroup initiated coverage on the stock with a Buy rating and a $2.60 price target.
    • Pardes Biosciences, Inc. (NASDAQ:PRDS) rose 9.6% to $1.26. JMP Securities initiated coverage on Pardes Biosciences with a Market Outperform rating and announced a price target of $9.
    • MediaCo Holding Inc (NASDAQ:MDIA) rose 5.3% to $1.1485 after the company said it has divested the assets of Fairway Outdoor LLC to Lamar Advertising Company for $78.6 million.
    • Oracle Corporation (NYSE:ORCL) gained 3% to $83.69 after the company reported better-than-expected results for its second quarter on Monday.


    Losers

    • Quotient Limited (NASDAQ:QTNT) fell 46% to $0.37. Quotient announced intent to voluntary delist from the Nasdaq Global Market.
    • Argo Blockchain plc (NASDAQ:ARBK) shares fell 38.1% to $0.4246. Argo Blockchain recently announced a November operational update..
    • Avaya Holdings Corp. (NYSE:AVYA) dropped 38% to $0.7149. Avaya disclosed certain information related to ongoing constructive discussions with financial stakeholders.
    • Midatech Pharma plc (NASDAQ:MTP) fell 30% to $1.17. Midatech Pharma PLC proposed acquisition of Bioasis Technologies Inc.
    • China Jo-Jo Drugstores, Inc. (NASDAQ:CJJD) shares dipped 29% to $5.05 after gaining around 115% on Monday.
    • Getaround, Inc. (NYSE:GETR) fell 28.8% to $1.46 after dropping 32% on Monday. Getaround recently announced closing of business combination with InterPrivate II Acquisition Corp.
    • Edible Garden AG Incorporated (NASDAQ:EDBL) fell 24.4% to $0.3225 after jumping over 59% on Monday.
    • Clovis Oncology, Inc. (NASDAQ:CLVS) dropped 24% to $0.1521. Clovis Oncology voluntarily initiated a Chapter 11 proceeding in the U.S. Bankruptcy Court and will seek to sell its assets through a court-supervised sales process.
    • Aptevo Therapeutics Inc. (NASDAQ:APVO) fell 23.2% to $3.00. Aptevo Therapeutics shares surged 14% on Monday after the company announced that APVO436, in combination with venetoclax and azacitidine, achieved a 100% clinical benefit rate in venetoclax treatment naïve AML patients.
    • Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) dropped 23% to $8.31.
    • Hyperfine, Inc. (NASDAQ:HYPR) shares fell 21.9% to $0.9601. Hyperfine, on December 6, committed to organizational restructuring designed to decrease costs, create streamlined organization to support business, and has terminated approximately 13% of its global workforce.
    • Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) dropped 20% to $0.80.
    • Harpoon Therapeutics, Inc. (NASDAQ:HARP) dipped 20% to $1.1250. Harpoon Therapeutics recently announced it presented updated interim results at ASH 2022 for novel T cell engager HPN217 in relapsed/refractory multiple myeloma.
    • HTG Molecular Diagnostics, Inc. (NASDAQ:HTGM) declined 19.8% to $0.8180.
    • Enzo Biochem, Inc. (NYSE:ENZ) fell 19.4% to $1.49 following Q1 results.
    • Ambrx Biopharma Inc. (NYSE:AMAM) shares fell 19.2% to $2.3099 after dipping 37% on Monday.
    • Adamas One Corp. (NASDAQ:JEWL) shares fell 17.3% to $3.9250.
    • Curis, Inc. (NASDAQ:CRIS) fell 17% to $0.5399. Curis shares announced additional clinical data from the TakeAim Leukemia study of emavusertib.
    • Bone Biologics Corporation (NASDAQ:BBLG) dropped 16.8% to $0.2446.
    • SeqLL Inc. (NASDAQ:SQL) fell 16.2% to $0.44.
    • The Lion Electric Company (NYSE:LEV) fell 14.5% to $2.2810. Lion Electric reported pricing of 19,685,040 unit offering at $2.54 per unit.
    • Aerovate Therapeutics, Inc. (NASDAQ:AVTE) fell 11.5% to $27.00. Aerovate Therapeutics, last month, posted a Q3 loss of $0.56 per share.
    • Nikola Corporation (NASDAQ:NKLA) fell 11.5% to $2.0699.
    • Silvergate Capital Corporation (NYSE:SI) dropped 11.5% to $18.80. JP Morgan maintained Silvergate Capital with an Overweight and lowered the price target from $50 to $30.
    • Engine Gaming and Media, Inc. (NASDAQ:GAME) fell 9.3% to $0.9584 after jumping 95% on Monday. The company last Thursday announced it has entered into an agreement to combine with GameSquare Esports.
    • JetBlue Airways Corporation (NASDAQ:JBLU) fell 8.6% to $7.03 as the company said it expects Q4 revenue per ASM at the low end of its guidance range.

    Also check this out Ethereum Jumps Above This Major Level; Toncoin Emerges As Top Gainer.

    Get the next $ACMR alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ACMR
    $AMAM
    $ANGI
    $APVO

    CompanyDatePrice TargetRatingAnalyst
    Oracle Corporation
    $ORCL
    4/24/2026$225.00Outperform
    Wedbush
    Corvus Pharmaceuticals Inc.
    $CRVS
    4/17/2026$40.00Buy
    Goldman
    Fluence Energy Inc.
    $FLNC
    4/17/2026$8.00Neutral → Sell
    UBS
    JetBlue Airways Corporation
    $JBLU
    4/16/2026$8.00Neutral → Buy
    Seaport Research Partners
    Oracle Corporation
    $ORCL
    4/10/2026Buy → Neutral
    Cleveland Research
    Summit Therapeutics Inc.
    $SMMT
    4/8/2026$45.00Buy
    Stifel
    Pinterest Inc.
    $PINS
    4/7/2026$27.00 → $25.00Overweight
    Wells Fargo
    Entrada Therapeutics Inc.
    $TRDA
    4/1/2026Overweight
    Cantor Fitzgerald
    More analyst ratings

    $ACMR
    $AMAM
    $ANGI
    $APVO
    SEC Filings

    View All

    SEC Form DEFA14A filed by Entrada Therapeutics Inc.

    DEFA14A - Entrada Therapeutics, Inc. (0001689375) (Filer)

    4/24/26 8:31:00 AM ET
    $TRDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form DEF 14A filed by Entrada Therapeutics Inc.

    DEF 14A - Entrada Therapeutics, Inc. (0001689375) (Filer)

    4/24/26 8:30:13 AM ET
    $TRDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13D/A filed by JetBlue Airways Corporation

    SCHEDULE 13D/A - JETBLUE AIRWAYS CORP (0001158463) (Subject)

    4/23/26 4:55:25 PM ET
    $JBLU
    Air Freight/Delivery Services
    Consumer Discretionary

    $ACMR
    $AMAM
    $ANGI
    $APVO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Wedbush initiated coverage on Oracle with a new price target

    Wedbush initiated coverage of Oracle with a rating of Outperform and set a new price target of $225.00

    4/24/26 8:06:10 AM ET
    $ORCL
    Computer Software: Prepackaged Software
    Technology

    Goldman initiated coverage on Corvus Pharmaceuticals with a new price target

    Goldman initiated coverage of Corvus Pharmaceuticals with a rating of Buy and set a new price target of $40.00

    4/17/26 8:10:40 AM ET
    $CRVS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Fluence downgraded by UBS with a new price target

    UBS downgraded Fluence from Neutral to Sell and set a new price target of $8.00

    4/17/26 8:08:09 AM ET
    $FLNC
    Industrial Machinery/Components
    Miscellaneous

    $ACMR
    $AMAM
    $ANGI
    $APVO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President St George Martin J converted options into 46,882 shares and covered exercise/tax liability with 23,934 shares, increasing direct ownership by 23% to 120,857 units (SEC Form 4) (withholding tax)

    4 - JETBLUE AIRWAYS CORP (0001158463) (Issuer)

    4/23/26 5:13:58 PM ET
    $JBLU
    Air Freight/Delivery Services
    Consumer Discretionary

    SEC Form 4 filed by General Counsel Corp Sec Mccarthy Eileen P

    4 - JETBLUE AIRWAYS CORP (0001158463) (Issuer)

    4/23/26 5:13:14 PM ET
    $JBLU
    Air Freight/Delivery Services
    Consumer Discretionary

    SEC Form 4 filed by Chief Financial Officer Hurley Ursula L

    4 - JETBLUE AIRWAYS CORP (0001158463) (Issuer)

    4/23/26 5:13:07 PM ET
    $JBLU
    Air Freight/Delivery Services
    Consumer Discretionary

    $ACMR
    $AMAM
    $ANGI
    $APVO
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for VOQUEZNA issued to PHATHOM PHARMACEUTICALS INC

    Submission status for PHATHOM PHARMACEUTICALS INC's drug VOQUEZNA (ORIG-1) with active ingredient VONOPRAZAN FUMARATE has changed to 'Approval' on 07/17/2024. Application Category: NDA, Application Number: 218710, Application Classification: Type 9 - New Indication Submitted as Distinct NDA, Consolidated with Original NDA after Approval

    7/18/24 10:52:01 AM ET
    $PHAT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for PONVORY issued to VANDA PHARMS INC

    Submission status for VANDA PHARMS INC's drug PONVORY (SUPPL-6) with active ingredient PONESIMOD has changed to 'Approval' on 06/05/2024. Application Category: NDA, Application Number: 213498, Application Classification: Labeling

    6/17/24 12:07:18 AM ET
    $VNDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for PONVORY issued to VANDA PHARMS INC

    Submission status for VANDA PHARMS INC's drug PONVORY (SUPPL-5) with active ingredient PONESIMOD has changed to 'Approval' on 06/05/2024. Application Category: NDA, Application Number: 213498, Application Classification: Labeling

    6/17/24 12:07:18 AM ET
    $VNDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACMR
    $AMAM
    $ANGI
    $APVO
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Corvus Pharmaceuticals Appoints Andrew C. Chan, M.D., Ph.D., to Board of Directors

    SOUTH SAN FRANCISCO, Calif., April 23, 2026 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company, announced today that Andrew C. Chan, M.D., Ph.D., has been appointed to the Company's Board of Directors. Dr. Chan recently served as Senior Vice President, Research Biology during a distinguished 25 year career at Genentech. In this role, he led biological research across all therapeutic areas, contributing to the development of several FDA-approved medicines for oncology, neurology and immunology. "The addition of Dr. Chan elevates the scientific perspective of our Board as we continue to identify and advance opportunities for ITK inhibi

    4/23/26 7:30:00 AM ET
    $CRVS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Vanda Pharmaceuticals Appoints Dr. Charles Duncan to its Board of Directors

    WASHINGTON, April 22, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ:VNDA) today announced the appointment of Charles Duncan, Ph.D. to its Board of Directors effective April 22, 2026. Following Dr. Duncan's appointment, Vanda's Board of Directors is now comprised of seven directors, six of whom are independent. Dr. Duncan is a highly experienced and respected leader in the life sciences and biotechnology sector," said Mihael H. Polymeropoulos, M.D., Vanda's President, CEO and Chairman of the Board. "We are excited to welcome him to our strong and independent Boa

    4/22/26 5:13:00 PM ET
    $VNDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Shoulder Innovations to Report First Quarter 2026 Financial Results on May 13, 2026

    GRAND RAPIDS, Mich., April 22, 2026 /PRNewswire/ -- Shoulder Innovations, Inc. ("Shoulder Innovations") (NYSE:SI), a commercial-stage medical technology company exclusively focused on transforming the shoulder surgical care market, today announced it will release financial results for the first quarter of 2026 after market close on Wednesday, May 13, 2026. Management will host a conference call to discuss financial results beginning at 4:30 p.m. ET / 1:30 p.m. PT on May 13, 2026. Those interested in listening to the conference call may do so by dialing (877) 407-8216 for domesti

    4/22/26 4:05:00 PM ET
    $SI
    Medical/Dental Instruments
    Health Care

    $ACMR
    $AMAM
    $ANGI
    $APVO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Glenbrook Capital Management bought $330,182 worth of shares (171,034 units at $1.93) (SEC Form 4)

    4 - SenesTech, Inc. (0001680378) (Issuer)

    3/17/26 8:10:19 PM ET
    $SNES
    Agricultural Chemicals
    Industrials

    Chief Financial Officer Points Jeffrey S. exercised 13,264 shares at a strike of $2.48 and bought $30,000 worth of shares (2,000 units at $15.00), increasing direct ownership by 27% to 70,785 units (SEC Form 4)

    4 - SHOULDER INNOVATIONS, INC. (0001699350) (Issuer)

    3/17/26 5:42:34 PM ET
    $SI
    Medical/Dental Instruments
    Health Care

    Director Buchholz Richard bought $14,840 worth of shares (1,000 units at $14.84), increasing direct ownership by 8% to 13,666 units (SEC Form 4)

    4 - SHOULDER INNOVATIONS, INC. (0001699350) (Issuer)

    3/17/26 5:34:29 PM ET
    $SI
    Medical/Dental Instruments
    Health Care

    $ACMR
    $AMAM
    $ANGI
    $APVO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Pinterest Inc.

    SC 13G/A - PINTEREST, INC. (0001506293) (Subject)

    12/6/24 10:11:26 AM ET
    $PINS
    Computer Software: Programming Data Processing
    Technology

    Amendment: SEC Form SC 13G/A filed by Gaotu Techedu Inc.

    SC 13G/A - Gaotu Techedu Inc. (0001768259) (Subject)

    11/27/24 6:02:40 AM ET
    $GOTU
    Other Consumer Services
    Real Estate

    Amendment: SEC Form SC 13G/A filed by BeyondSpring Inc.

    SC 13G/A - BeyondSpring Inc. (0001677940) (Subject)

    11/14/24 9:52:50 PM ET
    $BYSI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACMR
    $AMAM
    $ANGI
    $APVO
    Financials

    Live finance-specific insights

    View All

    Shoulder Innovations to Report First Quarter 2026 Financial Results on May 13, 2026

    GRAND RAPIDS, Mich., April 22, 2026 /PRNewswire/ -- Shoulder Innovations, Inc. ("Shoulder Innovations") (NYSE:SI), a commercial-stage medical technology company exclusively focused on transforming the shoulder surgical care market, today announced it will release financial results for the first quarter of 2026 after market close on Wednesday, May 13, 2026. Management will host a conference call to discuss financial results beginning at 4:30 p.m. ET / 1:30 p.m. PT on May 13, 2026. Those interested in listening to the conference call may do so by dialing (877) 407-8216 for domesti

    4/22/26 4:05:00 PM ET
    $SI
    Medical/Dental Instruments
    Health Care

    Wave Life Sciences First Quarter 2026 Financial Results Scheduled for April 28, 2026

    CAMBRIDGE, Mass., April 22, 2026 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (NASDAQ:WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, will host a live webcast and conference call at 8:30 a.m. ET on Tuesday, April 28, 2026, to review the company's first quarter 2026 financial results and provide business updates. The webcast and conference call may be accessed by visiting "Investor Events" on the investors section of the Wave Life Sciences website: https://ir.wavelifesciences.com/events-publications/events. Analysts planning to participate during the Q&A portion of the live call can join the conference call a

    4/22/26 8:30:00 AM ET
    $WVE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Schrödinger to Announce First Quarter 2026 Financial Results on May 5

    Schrödinger, Inc. (NASDAQ:SDGR) will report its first quarter 2026 financial results on Tuesday, May 5, 2026, after the financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET. The live webcast can be accessed in the "Investors" section of Schrödinger's website and will be archived for approximately 90 days following the event. About Schrödinger Schrödinger is transforming molecular discovery with its computational platform, which enables the discovery of novel, highly optimized molecules for drug development and materials design. Schrödinger's software platform is built on more than 30 years of R&D investment and is licensed by biotechnology, pharma

    4/21/26 8:30:00 AM ET
    $SDGR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACMR
    $AMAM
    $ANGI
    $APVO
    Leadership Updates

    Live Leadership Updates

    View All

    Corvus Pharmaceuticals Appoints Andrew C. Chan, M.D., Ph.D., to Board of Directors

    SOUTH SAN FRANCISCO, Calif., April 23, 2026 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company, announced today that Andrew C. Chan, M.D., Ph.D., has been appointed to the Company's Board of Directors. Dr. Chan recently served as Senior Vice President, Research Biology during a distinguished 25 year career at Genentech. In this role, he led biological research across all therapeutic areas, contributing to the development of several FDA-approved medicines for oncology, neurology and immunology. "The addition of Dr. Chan elevates the scientific perspective of our Board as we continue to identify and advance opportunities for ITK inhibi

    4/23/26 7:30:00 AM ET
    $CRVS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Vanda Pharmaceuticals Appoints Dr. Charles Duncan to its Board of Directors

    WASHINGTON, April 22, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ:VNDA) today announced the appointment of Charles Duncan, Ph.D. to its Board of Directors effective April 22, 2026. Following Dr. Duncan's appointment, Vanda's Board of Directors is now comprised of seven directors, six of whom are independent. Dr. Duncan is a highly experienced and respected leader in the life sciences and biotechnology sector," said Mihael H. Polymeropoulos, M.D., Vanda's President, CEO and Chairman of the Board. "We are excited to welcome him to our strong and independent Boa

    4/22/26 5:13:00 PM ET
    $VNDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    MediaCo Appoints Roberto Castro to Senior Vice President and Corporate Controller

    MediaCo Holding Inc. (NASDAQ:MDIA) today announced the appointment of Roberto Castro to Senior Vice President and Corporate Controller. Mr. Castro brings 30 years of media and entertainment sector experience along with extensive financial management expertise to the company. He joins MediaCo following a nearly 24-year career at Spanish Broadcasting System (SBS), where he served in various senior finance roles, including Vice President of Finance since 2015. Prior to joining SBS, he spent over six years at DIRECTV Latin America, where he held the roles of Accounting & Consolidation Manager and Senior Auditor. Previously, he served as an auditor at Coopers & Lybrand, LLP. He holds an MPA in

    4/20/26 9:00:00 AM ET
    $MDIA
    Broadcasting
    Consumer Discretionary

    $ACMR
    $AMAM
    $ANGI
    $APVO
    Insider purchases explained

    Analytical look into recent insider purchases

    View All

    What Led to the Purchase at Aerovate Therapeutics Inc. on Jun 20?

    Recently, on June 20, 2024, a notable insider purchase was made at Aerovate Therapeutics Inc. Director Ra Capital Management, L.P. bought $1,549,944 worth of shares, acquiring 928,110 units at $1.67 per share as reported in the SEC Form 4. Insider transactions like these are closely watched by investors as they can provide valuable insights into the company's prospects. When analyzing insider transactions, it is essential to look for patterns and trends among multiple transactions to gauge the overall sentiment within the company. Several other SEC Form 4 filings were made around the same time, on June 7, 2024, by various insiders at Aerovate Therapeutics Inc. These included transactions by

    6/21/24 3:23:59 PM ET
    $AVTE
    Biotechnology: Pharmaceutical Preparations
    Health Care